RTTNews | Mar 23, 2021 09:29AM EDT

09:28 Tuesday, March 23, 2021 (RTTNews.com) - Omeros Corp. (OMER) and Quantum Leap Healthcare Collaborative said that they began dosing of patients with narsoplimab in the I-SPY COVID-19 Trial. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative.

The trial will screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoid or reduce the duration of mechanical ventilation for critically ill COVID-19 patients.

Narsoplimab is Omeros' lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement. It is the only complement inhibitor invited to participate in the I-SPY COVID-19 Trial.

Narsoplimab has been administered under compassionate use to treat severely ill COVID-19 patients requiring mechanical ventilation, with impressive outcomes.

Read the original article on RTTNews ( https://www.rttnews.com/3179524/omeros-says-first-patients-dosed-with-narsoplimab-in-i-spy-covid-19-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved